BB's Stock Haven

[Daley~Mail]

$VYCO $1B+ Market Opportunity - First Real Treatment for Stroke-Related Vision Loss
Vycor's NovaVision helps victims of stroke and traumatic-brain injury permanently regain a
key portion of lost vision-field. This is the first treatment for what has been considered a
permanent and irreversible condition, and is backed by a strong scientific team, 15 years of
research and 20 clinical studies. It is FDA 510(k) cleared, has a strong patent portfolio, and
addresses a very large market in the United States, Europe, and around the world. Although
we believe it will take NovaVision several years to penetrate a big percentage of this market,
its multi-billion dollar size makes this product line a potential blockbuster for Vycor.

-Harbinger Research